UBS Group’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-2,802
Closed -$56.8K – 11355
2022
Q4
$56.8K Buy
2,802
+1,356
+94% +$20.8K ﹤0.01% 6648
2022
Q3
$16K Buy
1,446
+266
+23% +$3.02K ﹤0.01% 7754
2022
Q2
$14K Buy
1,180
+158
+15% +$2.55K ﹤0.01% 7457
2022
Q1
$22K Buy
1,022
+717
+235% +$19K ﹤0.01% 7372
2021
Q4
$10K Sell
305
-133
-30% -$3.71K ﹤0.01% 8842
2021
Q3
$11K Sell
438
-757
-63% -$13.5K ﹤0.01% 7933
2021
Q2
$16K Buy
+1,195
New +$14.8K ﹤0.01% 7605
2021
Q1
– Sell
-1,943
Closed -$16K – 9690
2020
Q4
$16K Buy
1,943
+221
+13% +$1.74K ﹤0.01% 7135
2020
Q3
$13K Buy
+1,722
New +$15.3K ﹤0.01% 6663
2020
Q1
– Sell
-964
Closed -$14K – 8581
2019
Q4
$14K Buy
+964
New +$14.1K ﹤0.01% 7108
2019
Q2
– Sell
-2,235
Closed -$30K – 8276
2019
Q1
$30K Buy
2,235
+689
+45% +$10K ﹤0.01% 5953
2018
Q4
$22K Sell
1,546
-2,069
-57% -$33.7K ﹤0.01% 6721
2018
Q3
$65K Buy
3,615
+1,631
+82% +$28.3K ﹤0.01% 5960
2018
Q2
$28K Sell
1,984
-1,916
-49% -$33.7K ﹤0.01% 6455
2018
Q1
$75K Buy
3,900
+2,604
+201% +$56.3K ﹤0.01% 5422
2017
Q4
$29K Buy
1,296
+1,078
+494% +$34.5K ﹤0.01% 6270
2017
Q3
$8K Buy
+218
New +$8.13K ﹤0.01% 7019

UBS Group's OPNT Position: Q1 2023 in Review

UBS Group sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 2,802 shares — an estimated $56.8K sold.

UBS Group first reported a position in OPNT in Q3 2017 and held it in 17 quarters. The position peaked at $75K in Q1 2018. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.

  • UBS Group reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • UBS Group sold 2,802 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $56.8K.
  • UBS Group first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 17 quarters.
  • UBS Group's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $75K in Q1 2018.
  • 0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.